Uterine Corpus Cancer Subcommittee

Purpose

The NRG Oncology Uterine Corpus Cancer Subcommittee’s purpose is to improve the live of patients with uterine cancer by designing and conducting practice-changing multi-institutional clinical trials and translational research. This committee focuses on developing and testing innovative advanced surgical, radiation oncology, and systemic (including chemotherapy and other targeted/biologic therapies) technologies for patients with gynecologic uterine malignancies. Additionally, the committee is committed to identifying and rectifying disparities in patient outcomes within this population.

The goals of this committee include developing national and international priorities, goals, and initiatives for the management of uterine cancer; developing and managing currently active and developing NRG clinical trials on the prevention, diagnosis, and treatment of uterine corpus cancers; and, fostering the advancement of promising therapeutics in development and exploring potential translational research and biomarker development for incorporation into future clinical trials. This committee strives to develop and implement standardized procedures needed to design and conduct a research protocol within NRG while identifying potential barriers, and potential solutions to improve enrollment to NRG clinical trials in uterine corpus cancers, including fostering international collaboration. This committee meets four times a year, twice in-person and two virtual interim meetings.

Uterine Corpus Cancer Subcommittee Leadership

Chair

Matthew Powell, MD

Vice Chair

Ann Klopp, MD

Working Groups

Gestational Trophoblastic Working Group

Cf/ctDNA Working Group

Protocol 210 Working Group

Core Committee Members

Core Members

Mariam AlHilli
Therese Youssef Andraos
Floor Backes
Victoria Bae-Jump
Emma L. Barber
Joyce Barlin
Dana M. Chase
Bradley R. Corr
Casey Cosgrove
Linda Duska
Britt Erickson
Ramez Eskander
Idalid Franco
Marina Frimer
Katherine Fuh
Chad A. Hamilton
Marilyn Huang
Anuja Jhingran
Sarah H. Kim
Lindsay M. Kuroki
Colton J. Ladbury
Lisa M. Landrum
Helen J. Mackay
Cara Mathews
David Miller
Amanda Nickels-Fader
Alexander B. Olawaiye
Brian C. Orr
Bhavana Pothuri
Allison Puechl
Bobbie J. Rimel
Andrea Russo
Brian Slomovitz
Jessica D. St. Laurent
Michael Toboni

Patient Representatives

Dana Moore

QOL Representative

Elizabeth Jewell

Medical Oncology Representative

Martee Hensley

Translational Science Liaison

Katherine C. Fuh

New Investigator Liaison

Joyce Barlin

Linda Duska

General Committee Members

General Members

Sarah Ackroyd
Amy Armstong
Jamie Bakkum-Gamez
Emma Barber
David Bender
Saveri Bhattacharya
Julia B. Blanter
Leslie S. Bradford
Susana Campos
Michael E. Carney
Tara Castellano
David Cella
Aine Clements
Christopher H. Chapman
Joshua Cohen
Bradley Corr
Janell Darby
Amanda Nickles Fader
Julia Fehniger
Peter Frederick
Valerie Galvan-Turner
Sarah Gill
Allison Gockley
Angela K. Green
Gregory Gressel
Craig E. Grossman
Michael Guy
Kosei Hasegawa
James Hoffman
Elizabeth Hopp
Krisha Howell
Megan L. G. Hutchcraft
Elizabeth Jewell
Paul Johannet
Sokbom Kang
Juraj Kavecansky
Namita Khanna
Christi Kim
Christine Kim
Min Kyu Kim
Emily Ko
Katherine Kurnit
Olivia Lara
Nita Lee
Kimberly Leslie
Jennifer MacDonald
Diana Miao
Larry Maxwell
Lindsey A. McAlarnen
Carolyn McCourt
Ida Micaily
Kathryn Mills
Jennifer Mueller
Carolyn Muller
David Mutch
Mario Javier Pineda
Lisa Rauh-Benoit
Bobbie Jo Rimel
Tyler Robin
Maria Rubinstein
Chelsea Salyer
Julian Schink
William Small
Brenna Swift
Edward Tanner
Sarah Temkin
Neil K. Taunk
Michael D. Toboni
Akila Viswanathan
Tilley Jenkins Vogel
Matthew K. Wagar
Boris Winterhoff
Aaron Wolfson
Catheryn Yashar

Reset all column filters

Study	Title	Status	Phase	Disease Category	Disease Site
GOG-0184	A RANDOMIZED PHASE III STUDY OF TUMOR VOLUME DIRECTED PELVIC PLUS OR MINUS PARA-AORTIC IRRADIATION FOLLOWED BY CISPLATIN AND DOXORUBICIN OR CISPLATIN, DOXORUBICIN AND PACLITAXEL FOR ADVANCED ENDOMETRIAL CARCINOMA	Terminated	III	Gynecologic [GY]	Uterine Corpus
GOG-0238	A Randomized Trial of Pelvic Irradiation with or Without Concurrent Weekly Cisplatin in Patients with Pelvic-Only Recurrence of Carcinoma of the Uterine Corpus	Complete	II	Gynecologic [GY]	Uterine Corpus
GOG-0277	A Phase III Randomized Trial of Gemcitabine (NSC# 613327) Plus Docetaxel (NSC# 628503) Followed by Doxorubicin (NSC# 123127) Versus Observation for Uterus-Limited, High Grade Uterine Leiomyosarcoma	Terminated	III	Gynecologic [GY]	Uterine Corpus
GOG-0286B	A Randomized Phase II/III Study of Paclitaxel/Carboplatin/Metformin (NSC#91485) Versus Paclitaxel/Carboplatin/Placebo as Initial Therapy for Measurable Stage III or IVA, Stage IVB, or Recurrent Endometrial Cancer	Complete	II/III	Gynecologic [GY]	Uterine Corpus
NRG-CC010	A Phase III Trial of the Impact of Sentinel Lymph Node Mapping On Patient Reported Lower Extremity Limb Dysfunction in Endometrial Cancer	Open to Accrual	III	Gynecologic [GY]	Uterine Corpus
NRG-GY008	A Phase II Evaluation of Copanlisib (BAY 80-6946) (IND #130822), a Selective Inhibitor of PI3KCA, in Patients with Persistent or Recurrent Endometrial Carcinoma Harboring PIK3CA Hotspot Mutations	Complete	II	Gynecologic [GY]	Uterine Corpus
NRG-GY011	A Randomized Surgical Window Pilot Investigation of the Relationship of Short Term Medroxyprogesterone Acetate (NSC #26386) Compared to Medroxyprogesterone Acetate Plus Entinostat (NSC #706995) on the Morphologic, Biochemical, and Molecular Changes in Primary Endometrioid Adenocarcinoma of the Uterine Corpus	Terminated	II	Gynecologic [GY]	Uterine Corpus
NRG-GY012	A Randomized Phase II Study Comparing Single-Agent Olaparib, Single Agent Cediranib, and the Combinations of Cediranib/Olaparib, Olaparib/Durvalumab (MEDI4736), Cediranib/Durvalumab (MEDI4736), Olaparib/AZD5363 (Capivasertib) in Women with Recurrent, Persistent or Metastatic Endometrial Cancer.: A Platform Trial for Women with Recurrent or Persistent Endometrial Cancer	Closed to Accrual	II	Gynecologic [GY]	Uterine Corpus
NRG-GY018	A Phase III Randomized, Placebo-Controlled Study of Pembrolizumab (MK-3475, NSC #776864) in Addition to Paclitaxel and Carboplatin for Measurable Stage III or IVA, Stage IVB or Recurrent Endometrial Cancer	Closed to Accrual & Treatment	III	Gynecologic [GY]	Uterine Corpus
NRG-GY020	A Phase III Randomized Trial of Radiation +/- Pembrolizumab (MK-3475) for Newly Diagnosed Early Stage High Intermediate Risk Mismatch Repair Deficient (dMMR) Endometrioid Endometrial Cancer	Closed to Accrual & Treatment	III	Gynecologic [GY]	Uterine Corpus
NRG-GY025	A Randomized Phase II Trial of Nivolumab and Ipilimumab Compared to Nivolumab Monotherapy in Patients with Deficient Mismatch Repair System Recurrent Endometrial Carcinoma	Open to Accrual	II	Gynecologic [GY]	Uterine Corpus
NRG-GY026	A Phase III Study of Paclitaxel/Carboplatin Alone or Combined with Either Trastuzumab and Hyaluronidase-oysk (HERCEPTIN HYLECTA) or Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf (PHESGO) in HER2 Positive, Stage I-IV Endometrial Serous Carcinoma or Carcinosarcoma	Open to Accrual	III	Gynecologic [GY]	Uterine Corpus
NRG-GY028	A Phase IB and Randomized Phase II Trial of Megestrol Acetate with or Without Ipatasertib in Recurrent or Metastatic Endometrioid Endometrial Cancer	Closed to Accrual	I/II	Gynecologic [GY]	Uterine Corpus
NRG-GY031	A Phase 1B Study of Combination ATR (M1774) and BET Inhibition (ZEN003694) to Exploit ARID1A Loss in Recurrent Ovarian and Endometrial Cancer	Open to Accrual	I	Gynecologic [GY]	Uterine Corpus
NRG-GY032	A Phase II Study of Tailored Adjuvant Therapy in Pole-Mutated and p53-Wildtype/NSMP Early-Stage Endometrial Cancer (RAINBO BLUE & TAPER)	Open to Accrual	II	Gynecologic [GY]	Uterine Corpus
NRG-GY035	A Randomized Phase III Trial of Carboplatin, Paclitaxel, Pembrolizumab Versus Carboplatin, Paclitaxel, Bevacizumab Versus Carboplatin, Paclitaxel, Pembrolizumab, Bevacizumab in the Treatment of pMMR, TP53 Mutated Advanced or Recurrent Endometrial Cancer	Open to Accrual	III	Gynecologic [GY]	Uterine Corpus
RTOG-1203	A Randomized Phase III Study of Standard vs. IMRT Pelvic Radiation for Post-Operative Treatment of Endometrial and Cervical Cancer (TIME-C)	Terminated	III	Gynecologic [GY]	Other

Support NRG Oncology.
Help Our Cause.

We are a leading protocol organizations within the National Clinical Trials Network and we seek to improve the lives of cancer patients by conducting practice-changing, multi-institutional clinical and translational research. Learn More

Donate Today

NRG Oncology Foundation, Inc, is a nonprofit, tax-exempt foundation. Donations to NRG Oncology help us conduct this important mission, and are tax-deductible to the extent permitted by law.